SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
After hours
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverPFE
HealthcareNYSEUSD

Pfizer Inc.

$0012345678900123456789.0012345678900123456789-3.5%
52w low (est.) $20.73$31.06 52w high (est.)
Peers
Market data
Market cap
$137.76B
52-week range
$23.11 – $28.75
Beta (vs market)
0.31
Sector
Healthcare
Valuation
P/E ratio
18.5x
DCF fair value
$35.00
Margin of safety
+39.2%
Forward P/E
8.5x
PEG ratio
2.81
Dividend yield
7.12%
Quality & efficiency
Moat score
60/100
Return on equity
8.3%
Profit margin
11.8%
Debt / equity
0.72
Growth & analysts
Revenue growth (YoY)
+5.4%
Analyst target
$29.02
Target upside
+15.4%
Analysts covering
26

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valuation

ValueGrowthProfitHealthIncome65QUALITY
Overall Rating
61
Buy
Buy
Moat Score60
DCF Intrinsic Value
$35.00+39.2% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$137.76B
P/E Ratio
18.5
Dividend Yield
7.12%
Revenue Growth
+5.4%
Profit Margin
11.8%
ROE
8.3%
Debt / Equity
0.72
Beta
0.31
Beaten DownValueDividend Aristocrats
vs Healthcare sector:P/E 18 vs 28 · cheaperMoat 60 vs 7Yield 7.12% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · PFE